trending Market Intelligence /marketintelligence/en/news-insights/trending/tlej6po6jvlt9pgdiwhzag2 content esgSubNav
In This List

Ra Pharmaceuticals prices $50.4M common stock offering

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Ra Pharmaceuticals prices $50.4M common stock offering

Ra Pharmaceuticals Inc. priced its offering of 8.4 million shares at $6 apiece to raise about $50.4 million in gross proceeds.

The Cambridge, Mass.-based biopharmaceutical company granted the underwriters an option to buy up to an additional 1,260,000 common shares.

The company plans to use the net proceeds to fund its phase 2 trial of RA101495 to treat generalized myasthenia gravis — a neuromuscular disease causing skeletal muscle weakness — for other pipeline programs, and for working capital and general corporate purposes.

The offering is expected to close Feb. 16, subject to customary closing conditions.